Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

AUTOR(ES)

Diaz Romero, J

RESUMO

Meningococcal meningitis is a severe, life-threatening infection for which no adequate vaccine exists. Current vaccines, based on the group-specific capsular polysaccharides, provide short-term protection in adults against serogroups A and C but are ineffective in infants and do not induce protection against group B strains, the predominant cause of infection in western countries, because the purified serogroup B polysaccharide fails to elicit human bactericidal antibodies. Because of the poor immunogenicity of group B capsular polysaccharide, different noncapsular antigens have been considered for inclusion in a vaccine against this serogroup: outer membrane proteins, lipooligosaccharides, iron-regulated proteins, Lip, pili, CtrA, and the immunoglobulin A proteases. Alternatively, attempts to increase the immunogenicity of the capsular polysaccharide have been made by using noncovalent complexes with outer membrane proteins, chemical modifications, and structural analogs. Here, we review the strategies employed for the development of a vaccine for Neisseria meningitidis serogroup B; the difficulties associated with the different approaches are discussed.

Documentos Relacionados

• Safety and immunogenicity of a group 29E meningococcal capsular polysaccharide vaccine in adults.
• Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.
• Peptide mimicry of the meningococcal group C capsular polysaccharide.
• Leishmaniasis: Current Status of Vaccine Development
• Immunogenicity and Safety Testing of a Group B Intranasal Meningococcal Native Outer Membrane Vesicle Vaccine